Questions?1-833-393-4363
Questions?1-833-393-4363
*Verana Health® data October 2024.
†wet AMD: Clinical studies showed people on VABYSMO gained vision on an eye chart (6 letters on average), similar to those on aflibercept 2 mg through year 1. DME: Clinical studies showed people on VABYSMO gained vision on an eye chart (11 letters on average), similar to those on aflibercept 2 mg through year 1. RVO: Clinical studies showed people on VABYSMO gained vision on an eye chart (17 letters on average), similar to those on aflibercept 2 mg over 6 months.
‡VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.